{"name":"Protein Sciences Corporation","slug":"protein-sciences-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"FluBlok Influenza Vaccination","genericName":"FluBlok Influenza Vaccination","slug":"flublok-influenza-vaccination","indication":"Prevention of influenza illness caused by influenza A and B viruses in adults 18 years of age and older","status":"phase_3"},{"name":"Fluarix Quadrivalent® Influenza Virus Vaccine","genericName":"Fluarix Quadrivalent® Influenza Virus Vaccine","slug":"fluarix-quadrivalent-influenza-virus-vaccine","indication":"Seasonal influenza prevention in adults and children ≥6 months of age","status":"phase_3"},{"name":"Flublok Quadrivalent Influenza Vaccine","genericName":"Flublok Quadrivalent Influenza Vaccine","slug":"flublok-quadrivalent-influenza-vaccine","indication":"Prevention of influenza illness caused by influenza A and B viruses in adults 18 years and older","status":"phase_3"},{"name":"Panblok","genericName":"Panblok","slug":"panblok","indication":"Other","status":"phase_1"},{"name":"rHA adjuvant","genericName":"rHA adjuvant","slug":"rha-adjuvant","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Flublok® Quadrivalent Influenza Virus Vaccine","genericName":"Flublok® Quadrivalent Influenza Virus Vaccine","slug":"flublok-quadrivalent-influenza-virus-vaccine","indication":"Active immunization against influenza disease caused by influenza A and B virus strains in adults 18 years of age and older","status":"phase_3"}]}],"pipeline":[{"name":"FluBlok Influenza Vaccination","genericName":"FluBlok Influenza Vaccination","slug":"flublok-influenza-vaccination","phase":"phase_3","mechanism":"FluBlok is a recombinant influenza vaccine that stimulates the immune system to produce antibodies against influenza virus surface proteins.","indications":["Prevention of influenza illness caused by influenza A and B viruses in adults 18 years of age and older"],"catalyst":""},{"name":"Fluarix Quadrivalent® Influenza Virus Vaccine","genericName":"Fluarix Quadrivalent® Influenza Virus Vaccine","slug":"fluarix-quadrivalent-influenza-virus-vaccine","phase":"phase_3","mechanism":"Fluarix Quadrivalent stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection.","indications":["Seasonal influenza prevention in adults and children ≥6 months of age"],"catalyst":""},{"name":"Flublok Quadrivalent Influenza Vaccine","genericName":"Flublok Quadrivalent Influenza Vaccine","slug":"flublok-quadrivalent-influenza-vaccine","phase":"phase_3","mechanism":"Flublok Quadrivalent stimulates immune response against four influenza virus strains by presenting recombinant hemagglutinin antigens produced in insect cells.","indications":["Prevention of influenza illness caused by influenza A and B viruses in adults 18 years and older"],"catalyst":""},{"name":"Flublok® Quadrivalent Influenza Virus Vaccine","genericName":"Flublok® Quadrivalent Influenza Virus Vaccine","slug":"flublok-quadrivalent-influenza-virus-vaccine","phase":"phase_3","mechanism":"Flublok stimulates the immune system to produce antibodies against four strains of influenza virus by presenting recombinant hemagglutinin antigens.","indications":["Active immunization against influenza disease caused by influenza A and B virus strains in adults 18 years of age and older"],"catalyst":""},{"name":"Panblok","genericName":"Panblok","slug":"panblok","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"rHA adjuvant","genericName":"rHA adjuvant","slug":"rha-adjuvant","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBEMDhMeTkyalZiZ0V3bU5LZEVFaHFPUVRMcWNlckN0TmFvY24tTkduQVFlbG03cFpvUnNZaXphOGVHdDJBclNfazI4OGhlRlltQWlXb28xdGNoMERiN0U1NlVqd3VWYkp0TVlJZ1VjZ2daVV9O?oc=5","date":"2026-01-28","type":"pipeline","source":"understandingai.org","summary":"An unlikely ally for open-source protein-folding models: Big Pharma - understandingai.org","headline":"An unlikely ally for open-source protein-folding models: Big Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQajF5MUNsd0IyX1V1RTlGZE10UDhCQWNRWkZOTXRlcHZMa1Z3ODdqNkRidW5RLURnWFl4QWpkbkI2RnllLV9uVEk5bTVWNUdjSE1hQWJkU0NyM2NlVDlmRkt5aE9hbGtHSE40MVFudzdTb2QtdjIwWW9pMDhPbVhKVjF1T2ZOcGw0RVgzT2lVTDY0RXdYNnFzWjdKRkJZdEg5eXc?oc=5","date":"2026-01-06","type":"deal","source":"BioPharma Dive","summary":"Amgen buys protein-degrading startup Dark Blue for up to $840M - BioPharma Dive","headline":"Amgen buys protein-degrading startup Dark Blue for up to $840M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPRmVJVjNLTWpFVVJuSURSS01fU1RKaThpejBINEtULTQyRXZTQmZqWGctcjV0ZGtTdXFkTXZyamlhTXQ2WXEtZ2xxRVItam5LMDNrOGg4eFNvaTMyNHFyX0RJRHB6OHN4TkdiY2NYT2NXSERpcFBiU0xhZzYwbEJJVm0wUnV3cGJfWHFzSFkxMmw2d0EyYVJNb0loMzV0STBwdWxJQURiM0xmRjJQMmI1aGZtSjhIZjFYeUpKRlJNTHVLTlZBY0wybVpleGZqcmhkZnJYYnlXNnNINFpENWc?oc=5","date":"2025-12-17","type":"trial","source":"PetfoodIndustry","summary":"Bioiberica study validates bioactive peptides in Palbio hydrolyzed protein - PetfoodIndustry","headline":"Bioiberica study validates bioactive peptides in Palbio hydrolyzed protein","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOdVZnSnpPSDBoOVVBeDN6QWstSWZzOHQ3VjlOTVdoSmg0WG12bXJXZ2h1Tk9pU2NYQ3lveURlRUxZaHUtajB1bjQtZ2ZMSWNVRlNvRXdFbW1TNWRIZ2ltWmJpeWZjc1VmWFRNNTlqaVpkWGxxc0c0LS1hU2haU0o4dHEybFRral9zdWZpTmk5YVlJcnMyT0Iw?oc=5","date":"2025-10-28","type":"deal","source":"businesswire.com","summary":"Pharmaron Acquires Biortus in China - businesswire.com","headline":"Pharmaron Acquires Biortus in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOR0dPSW1UZl80SHlubElNdzRUSEJwbThNRDJZUi1oTVotRmw5UEhQSHRVN29YbVZqWmtYQmdBM1JsS01uRm1jSXdsTVdtUTRfSldWRVRrcUI4MmxmS2ZJTDRuRms2NVotU1lUeWhGblU0OXhOclRMMXJHRGZRZDR6bGNCNjdmSUxScjB4SG9rTGVGRFJYQnpTSmo2SHZkcUdXbkFmNVJOd19pNGNUa0taNmFCRjcxNEE?oc=5","date":"2025-10-20","type":"deal","source":"European Pharmaceutical Review","summary":"Merck acquires JSR Life Sciences chromatography business - European Pharmaceutical Review","headline":"Merck acquires JSR Life Sciences chromatography business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNQXRXOHd2aEc5QnhhVjQyY0tJNTFCZmtDbGd3T3kyTFRIMWU4NWhDSE96UFJpMjkwdVY2amNpUkxWTGlvNGE1OWVIZ3lyV3pUNWQ2UG90OG9Wc1BoNUNGcWdvdjEzdUNZblZYZ0JCNHVKZjNEcDMyWUFNNExla2cyaDB5eUVlQ3Vw?oc=5","date":"2025-10-15","type":"deal","source":"Merck Group","summary":"Merck to Acquire the Chromatography Business of JSR Life Sciences - Merck Group","headline":"Merck to Acquire the Chromatography Business of JSR Life Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOV3JjdUtmekZwbE9EbU5HSVJ0TlJRSGpNbklJZUlFTEg4SEg5Z0liREdYd2tyWHlUYjFQUHZpdjJUNEJjVnJ4Zk5XWkxJSHhmRWlpdFhJTjRFX1VlQUhBaWt5RjQwRUZ0bm9qczNWMmRIVTBESERRb1RJckl1NE9NZVk4aVp0TEZfNmVvTktTblJfY1p6dHRyWkxIc18zWkxVbTdEbWZxS2pQclhJU3lOdkVDRHNCb3FpZjc2MnhkbXdiTDFS?oc=5","date":"2025-10-01","type":"trial","source":"Reuters","summary":"Bristol Myers, Takeda to pool data for AI-based drug discovery - Reuters","headline":"Bristol Myers, Takeda to pool data for AI-based drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNcjVxZHlkR1RqUjJEUFppejFOZGV3QTlSMjFXOW92WHp1dmNvNlk5YUhHS0Itdk9tV1M0TGQ2OHNaSXc4dTdvOUdpLXJFemswU3NRd1JNWGtfYXR4eVFhbzJJZUZfcjFPUVZKZm95QnVzNXVfRmpKdWgxeElFbHIyNXlWN2k4bVNiQV8ycUJudVQ3X3Jrdy1ieFVzWGdJS0RMY2xiTW5iSjQ3akZPMWRobkIzSQ?oc=5","date":"2025-07-25","type":"pipeline","source":"BioSpace","summary":"Protein Expression Technology Market Strengthens USD 5.58 Billion by 2034 - BioSpace","headline":"Protein Expression Technology Market Strengthens USD 5.58 Billion by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPejhoR1RPa2pwNlVSeUduRE1zSExHajJnaG1ySkF3UllUT0tIZGJGV2IwSXlnTjJvYXQ2S25GcUtoSE54XzB4WXY1SGxQdEY3UUtvQnd5TUZQVnNCTGR2NzFFLVpkSHNsalFzNEJUU0x0UjlESzBRWmZQaS12cmRWOGwwSGJzeUM4OVh2Y3VPeS1ydjdUM2x0d0V4aFloTU5ucVE?oc=5","date":"2024-07-03","type":"pipeline","source":"CT Insider","summary":"Parent company of a CT drugmaker founded in 1983 is moving its operations to Pennsylvania - CT Insider","headline":"Parent company of a CT drugmaker founded in 1983 is moving its operations to Pennsylvania","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQZkV6ZmFKSlhUY0oyY2JrQ0tOc0NiU1R4VHZvSUJwZlFISU5MUmV1NFlZbmVsMU9kRDhXUnQtZzk3VnlmZjBia1d2anNpWnBidzFOTHd6ZW9UdnRvdmdfdldDMFRtS3dtX1J5SlJvb0lobU82dUVkQVNXQjlJYkNjRnotOG9EelY3d2Qtel8xVEc1WGxqNFdHM1lJRmY2cXFUeDlZdUp4TQ?oc=5","date":"2018-01-04","type":"deal","source":"Fierce Pharma","summary":"Dispute brewing over exit of Protein Sciences CEO after Sanofi buyout - Fierce Pharma","headline":"Dispute brewing over exit of Protein Sciences CEO after Sanofi buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZmNyMThwM05FeTRMRTlLZ0lDLUg5a2diVXhCalB0R3cxMWlfNi02b1NYVks0S1hpeHJnNTRiVGdlYmZwVVlfQy1QbHFnRXZRLXRhWnExcFExSmZqZm54OGpPVWRRa1lXMkpMMG5EMF9Hcm16MjZIcTQ2UUF3Rk1sdVY3cS1LYXN2b2taYWt2d3pzSV9aYVJzSG1OVW9uajlUTC16V2Z1Znk?oc=5","date":"2018-01-02","type":"pipeline","source":"hartfordbusiness.com","summary":"Pharma exec Cox to leave Protein Sciences following Sanofi takeover - hartfordbusiness.com","headline":"Pharma exec Cox to leave Protein Sciences following Sanofi takeover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPYksyc2FEZDhzcUJtMm5ibGhjcTB0MXVpb21zb0RMNWtuT3pKeU1ndE5aRkJJc0FKdnB4YUFVbGRIeVFLaXJINllEWXQ4QlZDQ0FzcGhsSTZBRm1tSUg0MG9zekVfTjRyam5OV1NiaXV3M0VoZEdqd1pTQWZpS1lEaVVfRVlheXFRWFhZS2VyUElIajF5cWFnamIydnRUV0djUjVTRWtVS0l0ZWlUS0dVWGZFVWVjVkFyd3Jlb19JOS0wcE1lYTA4OXNVZktNQmhDSFl2WU40RW9TTVF0TXdHMExKbm9HNUI2WEcwRmN3WEU?oc=5","date":"2014-08-12","type":"pipeline","source":"prnewswire.com","summary":"Protein Sciences and Liomont Announce Licensing of Proprietary Influenza Vaccines for the Mexico Market - prnewswire.com","headline":"Protein Sciences and Liomont Announce Licensing of Proprietary Influenza Vaccines for the Mexico Market","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":4,"phase_1":2},"enrichmentLevel":0,"visitCount":12,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}